• 1
    deDuve, C. Lysosomes revisited. Eur J Biochem 1983;137:391.
  • 2
    Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-1131.
  • 3
    Goldstein JL, Brown MS, Anderson RGW, Russel DW, Schneider WJ. Receptor mediated endocytosis: concepts emerging from the LDL receptor system. Annu Rev Cell Biol 1979;1:1.
  • 4
    Goldstein JL, Dana SE, Faust JR, Beaudet AL, Brown ML. Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. J Biol Chem 1975;250:8487-8795.
  • 5
    Grabowski GA, Charnas LW, Du H. Lysosomal acid lipase deficiencies. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, et al. (eds). Metabolic and Molecular Bases of Inherited Disease, 9th ed. New York: McGraw-Hill; 2012.
  • 6
    Muntoni S, Wiebusch H, Jansen-Rust M, Rust S, Seedorf U, Schulte H, et al. Prevalence of cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol 2007;27:1866-1868.
  • 7
    Balwani M, Breen C, Enns GM, Deegan PB, Honzík T, Jones S, et al. Clinical effect and safety profile of recombinant human lysosomal acid lipase in patients with cholesteryl ester storage disease. Hepatology 2013; 58:950-957.
  • 8
    Du H, Dumanu M, Witte D, Grabowski GA. Targeted disruption of the mouse lysosomal acid lipase gene: a cholesteryl ester storage disease clinical phenotype and Wolman disease biochemistry. Hum Mol Genet 1998;7:1347-1354.
  • 9
    Du H, Levine M, Ganesa C, Witte DP, Cole ES, Grabowski GA. The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy. Am J Hum Genet 2005;77:1061-1074.